期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

ACEI与ARB联用治疗心衰的临床评价 被引量：2

下载PDF
导出
摘要 血管紧张素转换酶抑制剂 (ACEI)已经成为治疗心力衰竭的基本用药 ,血管紧张素II受体阻滞剂(ARB)也已经应用于心力衰竭的治疗。两者作用机制的异同点促使人们思考联合应用ACEI与ARB的临床价值及可行性 ,近年来一些大型的临床试验试图给出明确的答案 。
作者 王若琦 高路
机构地区 西安交通大学医学院
出处 《心脑血管病防治》 2004年第1期52-54,共3页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
关键词 血管紧张素转换酶抑制剂 血管紧张素Ⅱ受体阻滞剂 慢性心力衰竭
分类号 R541.6 [医药卫生—心血管疾病] R972 [医药卫生—药品]
  • 相关文献

参考文献12

  • 1[1]Pitt B,Segal R,Martinez F A,et al.Randomised trial of losartan versus captopril in patients over 65with heart failure(Evaluation Losartan in the Elderly Study.ELITE).Lancet,1997,349(9054):747-752.
  • 2[2]Pitt B,Poole-Wilson PA,Segal R.Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure:randomised trial-the Losartan Heart Failure Survival Study ELITE II.Lancet,2000,355(9215):1582-7.
  • 3[3]Krombach R S,Clair M J,Hendrick J W,et al.Angiotensin converting enzyme inhibition,AT1 receptor inhibition,and combination therapy with pacing induced heart failure:Effects on left ventricular performance and regional blood flow patterns.Cardiovasc Res,1998,38(3):631-645.
  • 4[4]Kim S,Yoshiyama M,Izumi Y,et al.Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardac remodeling,cardiac function,and survival in rat heart failure.Circulation,2001,103(1):148-154.
  • 5[5]Shen Y T,Wiedmann R T,GreenlandB D,et al.Combined effects of angiotension-converting enzyme inhibitors and angiotensin receptor antagonism in consiouspigs with congestive heart failure.Cardiovasc Res,1998,39(2):413-422.
  • 6[6]Struckman D R,Rivey M P.Combined therapy with an angiotensin-II receptor blocker and an angiotensin-converting enzyme inhibitor in heart failure.Ann Pharmacother,2001,35(3):242-248.
  • 7[7]McKelvie RS,Yusuf S,Pericak D,et al.Comparison of candesartan,enalapril,and their combination in congestive heart failure:Randomized evaluation of strategies for left ventricular dysfunction(RESOLVD)pilot study.The RESOLVD Pilot Study Investigators.Circulation,1999,100(10):1056-1064.
  • 8[8]Cohn JN,Tognoni G,Val-HeFT Investigators.Effect of the angiotensin blocker valsartan on morbidity and mortality in heart failure:the valsartan heart failure trial (Val-HeFT).N Engl J Med 2001,345(6):1667-1675.
  • 9[9]Baruch L,Anand I,Cohen IS,et al.Augmented short-and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure.Circulation,1999,99(20):2658-2664.
  • 10[10]Parley W W.How many medicines do patients with heart failure need?Circulation,2001,103(12):1611-1612.

同被引文献18

  • 1杜晔,孙蔚明.血管紧张素转换酶抑制剂与利尿剂联合应用对老年人肾脏功能的影响[J].现代中西医结合杂志,2004,13(15):1998-2000. 被引量：4
  • 2张言.血管紧张素转换酶抑制剂的临床应用分析[J].中西医结合心脑血管病杂志,2005,3(2):180-181. 被引量：14
  • 3陈少萍,秦永文,郑兴.联合用药——高血压病人血压控制达标的基本策略[J].药学服务与研究,2006,6(6):401-405. 被引量：15
  • 4汪谦.现代医学实验方法.北京:人民卫生出版社,1998,105-121
  • 5[4]Zeng C,Luo Y,Asieo LD,et al.Perturbation of D1 dopamine and AT1 receptor interaction in spontaneouslyhypertensive rats[J].Hypertension,2003,42(4):787-792.
  • 6[8]Segura J,Praga M,Campo C,et al.Combination is better than monotherapy with ACE inhibitor or arlgiotensin recep-tor antagonist at recommended doses[J].J Renin An-giotensin Aldosterone Syst,2003,4(1):43-47.
  • 7Peterson J G, Topol E J, Sapp S K, et al. Evaluation of the effects of aspirin combined with angiotensin-coverting enzyme inhibitors in patients with coronary artery disease[J]. Am J Med, 2000,109(5):371-377.
  • 8Leor J, Reicher-Reiss H, Goldbourt U, et al. Aspirin and mortality in patients treated with angiotensin-coverting enzyme inhibitors: a cohort study of 11 575 patients with coronary artery disease[J]. J Am Coll Cardiol, 1999,33 (7):1920- 1925.
  • 9Krombach R S,Clair M J, Hendrick J W,et al. Angiotensin converting enzyme inhibition, AT1 receptor inhibition, and combination therapy with pacing induced heart failure: effects on left ventricular performance and regional blood flow patterns[J]. Cardiovasc Res, 1998,38(3) : 631-645.
  • 10Swedberg K, Pfeffer M, Granger C, et al. Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators[J]. J Card Fail,1999,5(3):276-282.

引证文献2

二级引证文献3

心脑血管病防治
2004年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部